News

Sanofi Pasteur has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its Prophylactic vaccine against staphylococcus, including methicillin-resistant staphylococcus aureus or MRSA. Under

Xencor has obtained a milestone payment from Pfizer. The amount of the payment was not disclosed. The payment was triggered by the initiation of human clinical trials of

Pfizer has reported that the patients treated with Toviaz (fesoterodine fumarate) 8mg extended release tablets had greater and statistically reductions in urge urinary incontinence episodes at week 12

Intercell has reported that interim data from a phase II clinical trial investigating the vaccine candidate for the prevention of infections with the bacterium pseudomonas aeruginosa are available.

ChemoCentryx has initiated patient enrollment in a Phase 2 clinical trial of CCX354, an orally-bioavailable, small molecule drug, designed to specifically target the CCR1 chemokine receptor for the

BioSpecifics Technologies has reported top-line efficacy and safety results from a Phase 2b clinical trial of Xiaflex for the treatment of peyronie’s disease. The Phase 2b study, conducted

Hospira and Orchid Chemicals & Pharmaceuticals have announced an agreement for Hospira to acquire Orchid’s generic injectable finished-dosage form pharmaceuticals business for approximately $400m. The acquisition includes Orchid’s

Almac Discovery (Almac) has initiated Phase I clinical trial of the intranasal Granisetron product. The product, which uses Archimedes’ proprietary ChiSys delivery technology, is being developed as a

Array BioPharma (Array) and Amgen have entered into an agreement. The deal grants Amgen exclusive worldwide rights to Array’s small-molecule glucokinase activator program, including ARRY-403, currently being tested